These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 20926557)
1. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. Vigan R; Neil SJ J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557 [TBL] [Abstract][Full Text] [Related]
3. Vpu binds directly to tetherin and displaces it from nascent virions. McNatt MW; Zang T; Bieniasz PD PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949 [TBL] [Abstract][Full Text] [Related]
4. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity. Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. Petit SJ; Blondeau C; Towers GJ J Gen Virol; 2011 Dec; 92(Pt 12):2937-2948. PubMed ID: 21900423 [TBL] [Abstract][Full Text] [Related]
6. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700 [TBL] [Abstract][Full Text] [Related]
7. Lack of adaptation to human tetherin in HIV-1 group O and P. Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466 [TBL] [Abstract][Full Text] [Related]
8. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106 [TBL] [Abstract][Full Text] [Related]
9. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs. Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374 [TBL] [Abstract][Full Text] [Related]
10. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation. Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin. Fritz JV; Tibroni N; Keppler OT; Fackler OT Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210 [TBL] [Abstract][Full Text] [Related]
12. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048 [TBL] [Abstract][Full Text] [Related]
13. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625 [TBL] [Abstract][Full Text] [Related]
14. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. Jia X; Weber E; Tokarev A; Lewinski M; Rizk M; Suarez M; Guatelli J; Xiong Y Elife; 2014 Apr; 3():e02362. PubMed ID: 24843023 [TBL] [Abstract][Full Text] [Related]
15. Transmembrane interactions of HIV-1 Vpu and tetherin. Guo F; Liang C Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177 [TBL] [Abstract][Full Text] [Related]
16. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function. Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615 [TBL] [Abstract][Full Text] [Related]
17. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. Vigan R; Neil SJ J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465 [TBL] [Abstract][Full Text] [Related]
18. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions. Yoshida T; Koyanagi Y; Strebel K J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238 [TBL] [Abstract][Full Text] [Related]
19. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718 [TBL] [Abstract][Full Text] [Related]
20. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. Kueck T; Neil SJ PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]